Introduction
============

Cartilage tissues are degenerated and are destroyed in osteoarthritic joints, which are more prevalent in elderly individuals ([@b1-mmr-12-04-4877]). Although arthroplasty can efficiently relieve the symptoms of osteoarthritis, implant loosening is inevitable in the years following arthroplasty ([@b1-mmr-12-04-4877]). Tissue engineered cartilage has been suggested as an improved substitution for conventional arthroplasty. Therefore, it is necessary to understand the molecular mechanisms underlying cartilage generation and degeneration.

Subsequent to mesenchymal condensation, mesenchymal stem cells sense cell-cell and cell-extracellular matrix (ECM) contact, which is termed focal adhesion ([@b2-mmr-12-04-4877]), followed by differentiation into chondrocytes and expression of ECM. There are other exogenous stimuli and intracellular signaling pathways regulating chondrogenesis and cartilage degeneration, including the phosphoinositide 3-kinase(PI3K)-Akt, mammalian target of rapamycin (mTOR) and epidermal growth factor pathways ([@b3-mmr-12-04-4877]--[@b7-mmr-12-04-4877]).

MicroRNAs (miRNAs) are short, non-coding single-stranded RNAs, which have been identified as important post-transcriptional regulators. miRNAs specifically bind to the 3′-untranslational region (UTR) of target gene mRNAs by complementary base pairing in the RNA-induced silencing complex, and they degrade mRNA or repress the translation of target genes ([@b8-mmr-12-04-4877]). miRNAs are essential for multiple biological processes, including cartilage formation and degeneration ([@b9-mmr-12-04-4877]).

A previous study profiled the miRNA expression levels in chondrogenic human adipose-derived mesenchymal stem cells (hADSCs), and observed that the expression levels of miRNA-92a (miR-92a) were significantly altered ([@b10-mmr-12-04-4877]). The present study hypothesized that miR-92a is involved in chondrogenesis and cartilage degeneration, and investigated the presence and biological function of miR-92a in chondrogenesis and cartilage degeneration.

Materials and methods
=====================

The Ethics Committee of Sun Yat-Sen University (Guangzhou, China) approved the experiments performed in the present study. Procedures involving human subjects were performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from the patients prior to inclusion in the study. The experiments involving mice were performed in accordance with the Laboratory Animal Center of Sun Yat-Sen University and the Guide for the Care and Use of Laboratory Animals.

Primary chondrocyte isolation
-----------------------------

Subsequent to obtaining informed consent, primary human chondrocytes (PHCs) were isolated from the cartilage of patients undergoing hip surgery. The patients included two females, aged 31 and 24 years, who were undergoing surgery for a femoral neck fracture at the First Affiliated Hospital of Sun Yat-Sen University. Patients with degraded cartilages, local or systemic immunological disorders or tumors were excluded from the investigation. The cartilage was carefully cut into sections and digested sequentially in pronase (cat. no. 10165921001; Roche Diagnostics, Basel, Switzerland) for 90 min and collagenase P (cat. no. 11213865001; Roche Diagnostics) for \~7 h on a 37°C stirring-plate. The chondrocytes were then collected by centrifugation (1,000 × g for 3 min) of the digestion solution and then were rinsed with Ca/Mg-free phosphate-buffered saline (cat. no. 14190-094; Gibco Life Technologies, Paisley, UK) three times. The chondrocytes were seeded into flasks containing Dulbecco\'s modified Eagle\'s medium (DMEM/F12; cat. no. SH30023.01B; GE Healthcare Life Sciences, Logan, UT, USA) with 5% fetal bovine serum (FBS; cat. no. 12657; Gibco Life Technologies), 2% penicillin and streptomycin (cat. no. 15140-122; Gibco Life Technologies,) and ITS+ Premix (cat. no. 354352; BD Biosciences, Franklin Lakes, NJ, USA).

The isolation of primary mouse chondrocytes (PMCs) was performed, as previously reported ([@b11-mmr-12-04-4877]). A total of 25 male mice were purchased from the Laboratory Animal Center of Sun Yat-Sen University (Guangzhou, China), and were maintained in five isolator cages in pathogen-free conditions. Mice were fed by the Laboratory Animal Center, and maintained at 18--22°C under 12 h light/dark cycles, until the end of the experiments. The mice were washed with 70% ethanol prior to sacrifice. The mice were sacrificed via cervical dislocation under anesthesia with a sponge of 50 ml anhydrous diethyl ether (Laboratory Animal Center of Sun Yat Sen University). Cartilage was carefully collected from the femoral head, femoral condyle and tibial plateau, and was digested in 3 mg/ml collagenase D (cat. no. 11088866001; Roche Diagnostics) at 37°C with agitation for 90 min, followed by further digestion in collagenase D overnight. The cells were collected, filtered through a 48 *µ*m nylon mesh, and were then seeded into a culture flask at a density of 8,000 cells/cm^2^ in M199 (Gibco Life Technologies; 10% FBS, 1% penicillin and streptomycin).

Cell culture and chondrogenic differentiation
---------------------------------------------

The hADSCs were purchased from Cyagen Bioinformatics (Suzhou), Inc. (cat. no. HUXMD-01001; Taicang, China). The hADSCs were maintained to permit expansion in DMEM (Cyagen Bioinformatics (Suzhou), Inc. 11965--092; Gibco Life Technologies) with 10% FBS, 100 *µ*/ml penicillin and 100 mg/ml streptomycin at 37°C in 5% CO~2~ at saturated humidity. The cells were subcultured at 80% confluence and third generation cells were used for the subsequent characterization and chondrogenesis experiments.

The third generation hADSCs were harvested and resuspended in incomplete mesenchymal stem cell chondrogenic differentiation medium \[cat. no. GUXMX-90041; Cyagen Bioinformatics (Suzhou), Inc.; 194 ml basal medium, 20 *µ*l dexamethasone, 600 *µ*l ascorbic acid, 2 ml ITS, 200 *µ*l sodium pyruvate, 200 *µ*l proline, 2 ml transforming growth factor-β3\] at 2×10^7^ cells/ml. Droplets (12.5 *µ*l) were then carefully added to each well of a 24-well plate. The hADSCs were allowed to adhere at 37°C for 90 min, followed by the addition of 500 *µ*l chondrogenic differentiation medium ([@b10-mmr-12-04-4877],[@b12-mmr-12-04-4877]--[@b14-mmr-12-04-4877]), which was replaced every 3 days.

ATDC5 mouse cells (Riken Cell Bank, Ibaraki, Japan) were cultured with DMEM/F12, 5% FBS and 1% penicillin and streptomycin in a 37°C, 5% CO~2~ humidified atmosphere. The culture medium was replaced every 2 days and the cells were subcultured when cells reached 90--100% confluence during the expansion culture. All the experiments were completed within 20 passages. The chondrogenic differentiation was induced using ITS+ Premix ([@b15-mmr-12-04-4877]--[@b17-mmr-12-04-4877]). The chondrogenic culture medium was then replaced daily.

PHCs were cultured in DMEM/F12, 5% FBS, 1% penicillin and streptomycin and ITS+ at 37°C in a 5% CO~2~ humidified atmosphere.

The PMCs were cultured for expansion in M199 (cat. no. 11150-059; Gibco Life Technologies), 10% FBS, 1% penicillin and streptomycin, basic fibroblast growth factor (cat. no. 450-33; PeproTech, Oak Park, CA, USA) and epidermal growth factor (cat. no. 315-09; PeproTech), at 37°C in a 5% CO~2~ humidified atmosphere.

Interleukin-1β (IL-1β)-treated chondrocytes
-------------------------------------------

ATDC5 cells were maintained in chondrogenic medium with 1% ITS+ for 14 days at 37°C to form chondrogenic ATDC5 cells. Chondrogenic ATDC5 cells, PHCs and PMCs, at the fourth passage, were treated with recombinant IL-1β (cat. no. 200-01B; PeproTech) at 1 ng/ml for 4 h ([@b18-mmr-12-04-4877]--[@b20-mmr-12-04-4877]).

Morphological analysis
----------------------

The stained ATDC5 cells were fixed in formalin for 4 h at room temperature, and were stained with 1 mg/ml alcian blue 8GX for 20 min at room temperature, followed by examination using microscopy (Axio Imager Z1; Carl Zeiss AG, Oberkochen, Germany). The micromass was harvested at 0, 7 and 14 days. The macromorphology was examined by imaging with the M205 FA microscope \[Leica Microsystems AG, Heerbrugg, Switzerland\]. The micromass was fixed in formalin, embedded in paraffin, and stained with alcian blue ([@b14-mmr-12-04-4877]). Images were then captured under microscopy.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays
-----------------------------------------------------------------------------

Total RNA was extracted from the cells using an miRNeasy Mini kit (cat. no. 217004; Qiagen, Hilden, Germany), according to the manufacturer\'s instructions. The concentration and purity of the extracted RNA was analyzed using an Epoch Multi-Volume Spectrophotometer System (BioTek Instruments, Inc., Winooski, VT, USA). The cDNA of was obtained from mRNA and miRNAs using a PrimeScript^®^ miRNA cDNA Synthesis kit (cat. no. DRR350; Takara Bio, Inc., Otsu, Japan), according to the manufacturer\'s instructions.

Semi-qPCR was performed using SYBR^®^ Premix Ex Taq™ II (cat. no. DRR081; Takara Bio, Inc.) and a Bio-Rad IQ5 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The concentration of reagents and cycling conditions were according to the manufacturer\'s instructions. The cycles began at 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec. Ten nanograms of cDNA was added into the 25 *µ*l reaction volume. The primer sequences are presented in [Table I](#tI-mmr-12-04-4877){ref-type="table"}. The reverse primer for the miRNAs was Uni-miR qPCR Primer (cat. no. D352; Takara Bio, Inc.). Quality control was performed by monitoring the melting curve. Fold differences in mRNA expression were calculated using the ΔΔCt method ([@b21-mmr-12-04-4877]). All samples were measured in triplicate.

Transfection assays
-------------------

The condition and efficiency of transfection assays were verified using a CY3-labelled siR-Ribo™ Transfection Control (cat. no. siN05815122149-1-1; Guangzhou RiboBio Co., Ltd., Guangzhou, China). The ATDC5 cells (4×10^4^) were seeded into a 6-well plate with DMEM/F12 with 10% FBS, and were allowed to grow at 37°C until they had reached 50--70% confluence. Lipofectamine^®^ 2000 transfection reagent (cat. no. 11668; Invitrogen Life Technologies, Carlsbad, CA, USA) was then used to transfect the micrON™ mmu-miR-92a-3p mimic/inhibitor (cat. nos. miR10000539-1-2 and miR20000539-1-2; Guangzhou RiboBio Co., Ltd.) and micrON™ mimic/inhibitor negative control (cat. no. miR01101-1-2 and miR02101-1-2; Guangzhou RiboBio Co., Ltd.) into the cells, according to the manufacturer\'s instructions. Subsequent to 6 h transfection, chondrogenic differentiation was induced by replacing the medium with chondrogenic medium containing 1% ITS+ Premix.

Target prediction
-----------------

The potential target genes of miRNAs were predicted using the following online algorithms: miRanda (August 2010 release; <http://www.microrna.org/>), miRDB (MirTarget2_v4.0; <http://www.mirdb.org/miRDB/>), CLIP-Seq (2012-03-28; <http://mirtarclip.mbc.nctu.edu.tw/>) and TargetScan (version 6.2; <http://targetscan.org/>). Genes predicted by three or four separate algorithms were considered as potential target genes.

Based on these predicted target genes, the signaling pathways potentially regulated by miR-92a were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG, kobas2.0-20120208; <http://www.genome.jp/kegg/>) database and the possible function of miR-92a was predicted.

Statistical analysis
--------------------

All experiments were performed in triplicate. The quantitative data was expressed as the mean ± confidence interval (mean ± 1/2 CI). Differences between the groups were analyzed using Student\'s t-text or analysis of variance with SPSS, version 13.0 (SPSS, Inc., Chicago, IL, USA). The least significant difference test and Tamhane\'s T2 test were used in conditions with, and without, equal variances, respectively. The qualitative data was analyzed using Fisher\'s Exact test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Expression of miR-92a is elevated in chondrogenic differentiation
-----------------------------------------------------------------

The micromass produced from the hADSCs in chondrogenic medium was embedded in paraffin, cut into sections and stained with alcian blue ([Fig. 1A](#f1-mmr-12-04-4877){ref-type="fig"}). The expression levels of miR-92a, col2a1 and col10a1 increased in the chondrogenic hADSCs cells ([Fig. 1B](#f1-mmr-12-04-4877){ref-type="fig"}). The expression levels of mir-92a and the chondrogenic marker of col2a1 peaked at day 7 of chondrogenic induction, and the hypertrophic marker of col10a1 peaked at day 14.

Following 14 days of chondrogenic differentiation with ITS+ Premix, ATDC5 cells exhibited marked staining with alcian blue, compared with the cells without ITS+ Premix ([Fig. 2A and B](#f2-mmr-12-04-4877){ref-type="fig"}). The expression of col2a1 peaked at day 14, col10a1 peaked at day 28 and miR-92a peaked at day 21 ([Fig. 2C](#f2-mmr-12-04-4877){ref-type="fig"}).

Expression of miR-92a is increased in IL-1β-treated chondrocytes
----------------------------------------------------------------

Expression levels of miR-92a and mmp13 were upregulated in the PHCs and PMCs treated with 1 ng/ml IL-1β for 4 h, compared with the control ([Fig. 3A and B](#f3-mmr-12-04-4877){ref-type="fig"}). The expression levels of miR-92a and mmp13 were elevated, and that of col2a1 was suppressed in a time-dependent manner in the chondrogenic ATDC5 cells treated with 1 ng/ml IL-1β ([Fig. 3C](#f3-mmr-12-04-4877){ref-type="fig"}).

Col9a2 and aggrecan may be regulated by miR-92a
-----------------------------------------------

In order to investigate the effects of miR-92a on chondrogenesis, the expression levels of miR-92a were manipulated via transfection with a mimic or inhibitor. The altered expression of miR-92a affected chondrogenic markers, increasing the expression levels of col9a2 and aggrecan with the miR-92a mimic in a dose-dependent manner, compared with the untransfected control. In addition, the miR-193b-3p inhibitor reduced the expression levels of col9a2 and aggrecan in a dose-dependent manner, compared with the control ([Table II](#tII-mmr-12-04-4877){ref-type="table"}).

Predicted target genes, signaling pathways and functions of miR-92a
-------------------------------------------------------------------

The four algorithms, miRanda, miRDB, CLIP-Seq and TargetScan, were used for prediction of the miR-92a target genes. The general distribution of the predicted potential target genes is shown in [Fig. 4](#f4-mmr-12-04-4877){ref-type="fig"}. A total of 279 genes were predicted by three or four algorithms and were considered as potential target genes of miR-92a.

In addition to RT-qPCR, KEGG analysis was used to investigate the signaling pathways by which miR-92a may regulate chondrogenesis, based on the predicted potential target genes. The potential target genes were clustered based on their involvement in signaling pathways, and signaling pathways, which have been previously identified to be involved in chondrogenesis or cartilage degeneration were selected ([@b5-mmr-12-04-4877],[@b22-mmr-12-04-4877]--[@b25-mmr-12-04-4877]). The P-value was determined based on the number of potential target genes and the number of total genes in each signaling pathway. Of all of the predicted signaling pathways, the PI3K-Akt (P=0.064), ErbB (P=0.076) and focal adhesion kinase pathways (P=0.014), ECM-receptor interaction (P=0.024) and the mTOR signaling pathway (P=0.007) were identified as significant ([Table III](#tIII-mmr-12-04-4877){ref-type="table"}, [Fig. 5](#f5-mmr-12-04-4877){ref-type="fig"}).

Discussion
==========

Previous studies have suggested a role for miR-92a in renal tumorigenesis via the gene expression of VHL ([@b26-mmr-12-04-4877]), and in human acute promyelocytic leukemia via the expression of p63 ([@b27-mmr-12-04-4877]). An additional study identified the positive effects of miR-92a on the proliferation, differentiation and survival of chondrogenic progenitors via the targeting of nog3, an inhibitor of the bone morphogenetic protein (BMP) signaling pathway ([@b28-mmr-12-04-4877]). Although miR-92a was observed to contribute to chondrogenesis by enhancing the expression of col2a1 in the study by Ning *et al* ([@b28-mmr-12-04-4877]), no significant trend in the expression of col2a1 was not observed in the present study following transfection of either the miR-92a mimic or inhibitor. This discrepancy may be due to differences in experimental subjects and signaling pathways. In the study by Ning *et al* ([@b28-mmr-12-04-4877]), the BMP signaling pathway (smad1/5/8) and the inhibitor of BMP pathway (nog3) were observed to mediate the effects of miR-92a on *in vivo* pharyngeal chondrogenesis. In the present study, cultured ATDC5 cells were used for the investigation of miR-92a and chondrogenesis, which are associated with the autocrine transforming growth factor-β (smad2/3) signaling pathway ([@b29-mmr-12-04-4877]).

In the study by Ning *et al* ([@b28-mmr-12-04-4877]), the morphological defects resulting from the inhibition of nog3, one of the target genes of miR-92a\'s, were partially reversed by p53 co-inhibition, suggesting a contribution of miR-92a-nog3-apoptosis/proliferation to *in vivo* morphological regulation of pharyngeal cartilage formation. During chondrogenesis, high levels of type 9 collagen and aggrecan are expressed, along with additional matrix proteins to form the cartilage matrix, with col9a2 and aggrecan considered as chondrogenic markers ([@b30-mmr-12-04-4877]). Col9a2 and aggrecan were previously demonstrated to be associated with a number of diseases, including osteoarthritis ([@b31-mmr-12-04-4877],[@b32-mmr-12-04-4877]), degeneration of intervertebral discs ([@b33-mmr-12-04-4877],[@b34-mmr-12-04-4877]) and multiple epiphyseal dysplasia, characterized as the deformed deposition of cartilage at the ends of the bones ([@b32-mmr-12-04-4877],[@b35-mmr-12-04-4877],[@b36-mmr-12-04-4877]). The present study hypothesized that col9a2 may be another mediator of the degeneration of cartilage, followed by miR-92a knockdown. For the upstream regulation of col9a2 and aggrecan, Sox9 has been previously suggested as to be critical in initiating the expression of col9a2 and aggrecan ([@b37-mmr-12-04-4877]), although multiple enhancers have been observed to initiate expression of aggrecan ([@b38-mmr-12-04-4877]). However, more detailed information is required on the regulation of the expression levels of col9a2 and aggrecan in order to identify the cure for these diseases. In the present study, the results indicated that miR-92a may contribute to the upregulation of col9a2 and aggrecan, without enhancing the expression of sox9. These results provided novel insight into the upstream regulation of col9a2 and aggrecan, beyond what is already known about sox9 in relation to col9a2 and aggrecan. In addition, the results suggested another possible mechanism of a miR-92a-col9a2-cartilage deformity axis contributing to cartilage deformity following miR-92a knockdown. Further investigations are required in order to verify the effect of miR-92a on the *in vivo* expression levels of col9a2, aggrecan, and cartilage degeneration, and to determine the underlying mechanisms.

Several previous studies investigating miRNAs used one or two algorithms to predict the target genes, with subsequent mechanistic experiments, based on the predicted genes ([@b39-mmr-12-04-4877],[@b40-mmr-12-04-4877]). However, each of these widely used algorithms has an intrinsic false positive rate. The false positive rate is 22--31% for TargetScan, 24--39% for miRanda and \~30% for PicTar ([@b41-mmr-12-04-4877]). In the present study, four algorithms were used, and an intersection set of predicted genes from at least three algorithms was identified as a potential target gene. Based on the potential target genes, KEGG analysis was then used to predict several signaling pathways that possibly contribute to the effect of miR-92a on chondrogenesis. KEGG is a database, which is usually used for the prediction of function and signaling pathways from large scale molecular information of high-throughput experiments, including sequencing. This prediction method enables the minimization of false positive rates and assist in understanding the possible function of miR-92a in a wider context ([@b42-mmr-12-04-4877]). Investigations of underlying mechanisms can be performed using these predictions, including luciferase reporter assays of miR-92a and 3′-UTR of Akt1.

In conclusion, the present study demonstrated the presence of miR-92a in chondrogenesis and the chondrocyte response induced by IL-1β. The positive contribution of miR-92a in the expression of col9a2 and aggrecan was observed and the PI3K-Akt, ErbB and focal adhesion kinase pathways, ECM-receptor interaction, and mTOR signaling pathway were indicated as potential mediators of the effects of miR-92a on chondrogenesis and cartilage degeneration.
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![Chondrogenic adipose-derived mesenchymal stem cell micromass and the expression of miR-92a. (A) Subsequent to chondrogenesis for 7 days, the micromass was embedded in paraffin and cut into sections, followed by alcian blue staining (magnification, ×100). (B) RNA was isolated from the micromass and the expression levels of miR-92a, col2a1, and col10a1 were examined using reverse transcription-quantitative polymerase chain reaction. Error bars indicate the mean ± standard deviation. ^\*^P\<0.05. miR-92a, microRNA-92a.](MMR-12-04-4877-g00){#f1-mmr-12-04-4877}

![Chondrogenic ATDC5 and miR-92a expression. Chondrogenic ATDC5 cells were induced with ITS+ Premix, fixed with formalin and stained with alcian blue. (A) ATDC5 without ITS+ Premix exhibited low levels of alcian blue staining. (B) Chondrogenic ATDC5 cells exhibited more marked staining. (C) Expression levels of miR-92a, col2a1 and col10a1 in chondrogenic ATDC5 cells, examined using reverse transcription-quantitative polymerase chain reaction, compared with the negative control of ATDC5 without ITS+ Premix. Error bars indicate the mean ± standard deviation. ^\*^P\<0.05. miR-92a, microRNA-92a.](MMR-12-04-4877-g01){#f2-mmr-12-04-4877}

![Experssion of miR-92a in chondrocytes with IL-1β. Error bars indicate the mean ± standard deviation. (A) Expression of miR-92a was elevated in primary mouse chondrocytes treated with 1 ng/ml IL-1β for 4 h. (B) Expression of miR-92a was elevated in primary human chondrocytes treated with 1 ng/ml IL-1β for 4 h. No mmp13 was detected in the control group. (C) Expression of miR-92a was elevated in a time-dependent manner in the chondrogenic ATDC5 cells treated with 1 ng/ml IL-1β. miR-92a, microRNA-92a; IL-1β, interleukin-1β.](MMR-12-04-4877-g02){#f3-mmr-12-04-4877}

![Potential target genes of miR-92a, predicted using four algorithms. In order to minimize possible false positive prediction, only genes predicted by three or four algorithms were identified as potential target genes of miR-92a. miR-92a, microRNA-92a. Numbers refer to genes predicted by one of the four software program.](MMR-12-04-4877-g03){#f4-mmr-12-04-4877}

###### 

Predicted signaling pathways mediating the effects of miR-92a on chondrogenesis and cartilage degeneration. Predicted potential target genes of miR-92a are indicated by the red boxes. (A) PI3K-Akt, (B) ErbB and (C) focal adhesion signaling pathways were predicted based on the potential target genes of miR-92a. miR-92a, microRNA-92a; PI3K, phosphoinositide-3 kinase; mTOR, mammalian target of rapamycin. Predicted signaling pathways mediating the effects of miR-92a on chondrogenesis and cartilage degeneration. Predicted potential target genes of miR-92a are indicated by the red boxes. (D) ECM-receptor interaction and (E) mTOR signaling pathways were predicted based on the potential target genes of miR-92a. miR-92a, microRNA-92a; PI3K, phosphoinositide-3 kinase; mTOR, mammalian target of rapamycin.
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###### 

Primer sequences for reverse transcription-quantitative polymerase chain reaction.

  Gene                               Primer sequence (5′-3′)
  ---------------------------------- ----------------------------------
  Mmu/hsa-U6                         Forward: CTCGCTTCGGCAGCACA
  Reverse: AACGCTTCACGAATTTGCGT      
  Mmu-GAPDH                          Forward: TGTGTCCGTCGTGGATCTGA
  Reverse: TTGCTGTTGAAGTCGCAGGAG     
  Mmu/hsa-mir-92a                    TATTGCACTTGTCCCGGCCTG
  Mmu-col2a1                         Forward: CCCGCCTTCCCATTATTGAC
  Reverse: GGGAGGACGGTTGGGTATCA      
  Mmu-Sox9                           Forward: GGGGGTGAGCTTTGATTAATTC
  Reverse: GGGATTTAAGGCTCAAGGTGTTT   
  Mmu-Col10a1                        Forward: TTCTGCTGCTAATGTTCTTGACC
  Reverse: GGGATGAAGTATTGTGTCTTGGG   
  Mmu-Runx2                          Forward: ATGCTTCATTCGCCTCACAAA
  Reverse: GCACTCACTGACTCGGTTGG      
  Mmu-mmp13                          Forward: ATGCATTCAGCTATCCTGGCCA
  Reverse: AAGATTGCATTTCTCGGAGCCTG   
  Mmu-TNF-α                          Forward: GACGTGGAACTGGCAGAAGAG
  Reverse: TTGGTGGTTTGTGAGTGTGAG     
  Hsa-GAPDH                          Forward: GGAGCGAGATCCCTCCAAAAT
  Reverse: GGCTGTTGTCATACTTCTCATGG   
  Hsa-mmp13                          Forward: TCCTGATGTGGGTGAATACAATG
  Reverse: GCCATCGTGAAGTCTGGTAAAAT   
  Hsa-col2a1                         Forward: GAGGGCAATAGCAGGTTCACGTA
  Reverse: TGGGTGCAATGTCAATGATGG     
  Hsa-col10a1                        Forward: CACCAGGCATTCCAGGATTCC
  Reverse: AGGTTTGTTGGTCTGATAGCTC    

###### 

Relative mRNA expression levels in ATDC5 cells transfected with miR-92a mimic or inhibitor.

  Gene      Mimic (50 nM)   Mimic (100 nM)   Inhibitor (50 nM)   Inhibitor (100 nM)                                                             
  --------- --------------- ---------------- ------------------- -------------------- --------- ------ ------ --------- ------ ------ --------- ------
  Col2a1    0.89              0.24           0.14                0.74                   0.02    0.10   1.11     0.14    0.10   0.40   \<0.001   0.10
  Col10a1   1.10              0.17           0.06                1.11                   0.12    0.01   1.36   \<0.001   0.12   0.75   0.001     0.05
  Comp      0.61            \<0.001          0.07                1.24                   0.001   0.07   0.91     0.014   0.06   0.24   \<0.001   0.04
  Agc       3.52              0.001          0.62                6.89                 \<0.001   0.76   0.56   \<0.001   0.01   0.26   \<0.001   0.01
  Mmp-13    1.94              0.004          0.47                3.03                 \<0.001   0.14   1.00     0.994   0.03   0.67   \<0.001   0.02
  Col9a2    3.80              0.01           0.60                14.97                \<0.001   1.95   0.37   \<0.001   0.09   0.10   \<0.001   0.02
  Sox9      2.45            \<0.001          0.26                4.15                 \<0.001   0.50   1.18     0.15    0.16   1.10     0.40    0.23
  Runx2     1.59            \<0.001          0.16                2.16                 \<0.001   0.12   0.91     0.19    0.02   1.00     0.98    0.13

Expression of chondrogenic markers in ATDC5 cells transfected with miR-92a mimic or inhibitor at the indicated doses. Subsequent to transfection, ATDC5 cells were cultured in chondrogenic medium with ITS+ Premix for 4 days. Chondrogenic markers were measured using reverse transcription-quantitative polymerase chain reaction. Col9a2 and aggrecan were markedly upregulated in the miR-92a mimic groups, but were downregulated in the inhibitor groups, in a dose-dependent manner. No clear trends were observed for the other markers. miR-92a, microRNA-92a; SD, standard deviation.

###### 

Predicted signaling pathways, based on the potential target genes of miR-92a.

  Signaling pathway          P-value   Predicted target gene                                                            Function in chondrogenesis
  -------------------------- --------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PI3K-Akt                   0.064     Sgk3, Phlpp2, Pten, Pik3r3, Tsc1, Itga5, Itga6, Col1a2, Akt1, Bcl2l11and Itgav   Synergizing with runx2 to enhance normal hypertrophic differentiation and endochondral bone growth; promoting matrix synthesis and chondrocyte survival in adult articular chondrocytes ([@b22-mmr-12-04-4877]).
  ErbB                       0.076     Akt1, Pik3r3, Map2k4 and Braf                                                    Contributing to expression of aggrecanases and matrix metalloproteinases, delayed chondrogenesis and inhibition of the PI3K-Akt signaling pathway via downstream MAPK activation ([@b23-mmr-12-04-4877]).
  Focal adhesion             0.014     Rap1b, Pten, Pik3r3, Itga5, Itga6, Braf, Col1a2, Akt1 and Itgav                  Inhibiting chondrogenesis via expression of actin and activation of the RhoA/ROCK pathway ([@b24-mmr-12-04-4877]).
  ECM-receptor interaction   0.024     Col1a2, Sdc2, Itga5, Itga6 and Itgav                                             Inhibiting chondrogenesis via Itga5-mediated cellular-ECM interaction ([@b25-mmr-12-04-4877]).
  mTOR                       0.007     Pten, Tsc1, Pik3r3, Braf and Akt1                                                Reducing bone growth and hypertrophy; enhancing insulin-like growth factor I mediated proteoglycan synthesis in adult articular chondrocytes ([@b5-mmr-12-04-4877]).

PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; ROCK, Rho-associated protein kinase; ECM, extracellular matrix; mTOR, mammalian target of rapamycin.
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